What is Arctic Vision?
Arctic Vision is a China-based ophthalmic biotech enterprise dedicated to the research, development, and commercialization of breakthrough therapies for vision-threatening conditions. The company's core focus includes addressing high-prevalence diseases such as glaucoma and uveitic macular edema. By integrating a team of seasoned industry professionals with a robust pipeline, Arctic Vision aims to bridge the gap between advanced scientific innovation and patient accessibility. Their market position is defined by a commitment to high-impact clinical outcomes, serving as a vital link in the global ophthalmic healthcare ecosystem.
How much funding has Arctic Vision raised?
Arctic Vision has raised a total of $132M across 2 funding rounds:
Series A
$32M
Series B
$100M
Series A (2020): $32M with participation from Morningside Venture Capital
Series B (2021): $100M led by Tencent, Octagon Capital, New World Development Group, Dr. Adrian Cheng, Nan Fung Life Sciences, Pivotal bioVenture Partners China, Loyal Valley Capital, and The Morningside Group
Key Investors in Arctic Vision
Morningside Venture Capital
Morningside Group is a private equity and venture capital firm founded in 1986, known for its deep industry knowledge and commitment to social responsibility.
Tencent
A global technology conglomerate that invests in innovation across digital platforms, cloud computing, and healthcare ecosystems.
Nan Fung Life Sciences
A specialized investment arm of the Nan Fung Group, focusing on life sciences and biotechnology advancements within the Greater China region.
What's next for Arctic Vision?
With the recent infusion of capital, Arctic Vision is poised to scale its operational capabilities and expedite the clinical trial phases for its lead candidates. The strategic roadmap involves strengthening its commercial infrastructure and expanding its footprint in international markets. As the company matures, the focus will likely shift toward regulatory milestones and the successful market entry of its proprietary therapies. Investors and industry stakeholders are closely monitoring the firm's progress as it navigates the complexities of the ophthalmic biotech landscape, aiming to deliver long-term value through scientific excellence and strategic market penetration.
See full Arctic Vision company page
